Optiray (Ioversol)

What Is Optiray and What Is It Used For?

Quick Answer: Optiray is an iodinated X-ray contrast agent containing ioversol. It is injected intravenously before or during radiographic procedures to enhance the visibility of blood vessels, kidneys, and other internal organs on imaging studies.

Optiray belongs to the family of iodinated contrast media, which are essential tools in modern diagnostic radiology. The active substance, ioversol, is a non-ionic, low-osmolar contrast agent. This means it does not dissociate into ions in solution, which results in better tolerability and fewer side effects compared to older, ionic contrast agents. Each milliliter of Optiray 300 contains 636 mg of ioversol, equivalent to 300 mg of organically bound iodine.

The fundamental principle behind contrast media is straightforward: iodine atoms effectively block X-rays. When ioversol is injected into the bloodstream, it distributes throughout the vascular system and into organs that receive blood supply. This creates density differences that allow radiologists to visualize structures that would otherwise be difficult or impossible to distinguish on plain X-ray images or unenhanced CT scans.

Optiray is approved and used for several types of diagnostic imaging procedures in both adults and children:

• Angiography – Imaging of arteries and veins to detect blockages, aneurysms, or other vascular abnormalities. This includes coronary angiography, peripheral angiography, and cerebral angiography.
• Urography (intravenous pyelography) – Imaging of the kidneys, ureters, and bladder to evaluate kidney function, detect kidney stones, or identify structural abnormalities of the urinary tract.
• Computed Tomography (CT) – Contrast-enhanced CT scans of virtually any body region, including the brain, chest, abdomen, and pelvis, to detect tumors, infections, bleeding, or other pathology (approved for adults).

Optiray is administered exclusively by qualified healthcare professionals in hospital or clinical settings equipped for radiographic procedures. The solution is warmed to body temperature before injection to improve patient comfort and reduce the viscosity of the contrast medium, allowing smoother injection. The contrast agent is typically injected as a bolus (single rapid injection) or by continuous infusion, depending on the type of examination being performed.

It is important to understand that Optiray is a diagnostic tool, not a treatment. It does not cure or treat any disease but provides the radiologist with crucial visual information to make accurate diagnoses. The lowest dose necessary to produce adequate diagnostic images is always used, following the ALARA (As Low As Reasonably Achievable) principle common in radiological practice.

What Should You Know Before Receiving Optiray?

Quick Answer: Before receiving Optiray, your doctor needs to know about any allergies, thyroid conditions, kidney disease, diabetes, or other medical conditions. Certain medications, particularly metformin, must be adjusted or stopped before the procedure.

Contraindications

Optiray must not be used in the following situations:

• Allergy to iodinated contrast media – If you have had a previous allergic reaction to any iodine-containing contrast agent, or if you are allergic to any of the excipients in Optiray, you must not receive this medication. Allergic reactions can range from mild skin rashes to life-threatening anaphylaxis.
• Untreated hyperthyroidism – Optiray contains iodine, which can worsen an overactive thyroid gland. If you have untreated or uncontrolled hyperthyroidism, the additional iodine load from the contrast agent can trigger a thyroid storm, a potentially fatal condition.

Warnings and Precautions

Inform your physician or radiologist before receiving Optiray if you have any of the following conditions, as they may increase the risk of adverse effects or require special monitoring:

• Asthma or allergic history – Patients with asthma, hay fever, or a history of allergic reactions (including nausea, vomiting, low blood pressure, or skin symptoms from previous contrast media exposure) have a significantly higher risk of developing adverse reactions to iodinated contrast agents. Premedication with corticosteroids and antihistamines may be considered.
• Cardiovascular disease – Heart failure, high blood pressure, circulatory disorders, previous stroke, or advanced age increase the risk of cardiovascular complications during contrast administration.
• Diabetes mellitus – Diabetes, especially in combination with kidney disease, increases the risk of contrast-induced nephropathy. Special protocols for hydration and monitoring are essential.
• Kidney or liver disease – Impaired renal function is a major risk factor for contrast-induced acute kidney injury (CI-AKI). Kidney function tests (serum creatinine, estimated glomerular filtration rate) should be performed before administration.
• Brain injury or neurological conditions – Patients with brain lesions, seizure disorders, or compromised blood-brain barrier may be at increased risk of neurological complications.
• Multiple myeloma and paraproteinemia – Patients with these bone marrow disorders may be at increased risk of renal failure following contrast administration due to protein precipitation in renal tubules.
• Sickle cell disease – Iodinated contrast media may promote sickling in patients with sickle cell disease, potentially triggering a vaso-occlusive crisis.
• Pheochromocytoma – Patients with this adrenal tumor are at risk of a hypertensive crisis during contrast injection. Alpha-adrenergic blockade should be established before the procedure.
• Homocystinuria – Elevated homocysteine levels increase the risk of thrombotic events during vascular procedures involving contrast media.

Pregnancy and Breastfeeding

Pregnancy: If you are or suspect you may be pregnant, inform your doctor before the procedure. Optiray should only be used during pregnancy when absolutely necessary, as iodinated contrast agents cross the placenta and may affect the developing fetus, particularly the fetal thyroid gland. The potential benefits must clearly outweigh the risks. If Optiray is administered during pregnancy, neonatal thyroid function should be monitored after birth.

Breastfeeding: Breastfeeding should be discontinued for 24 hours after the injection of Optiray, as there is insufficient data regarding the excretion of ioversol in human breast milk and its potential effects on the nursing infant. Breast milk expressed during this period should be discarded. Consult your physician or radiologist for specific guidance.

Driving and Operating Machinery

Do not drive or operate machinery for at least one hour after receiving Optiray. Symptoms such as dizziness, drowsiness, faintness, and visual disturbances have been reported following contrast administration. If you experience any of these effects, refrain from activities requiring concentration and good reaction time until symptoms have completely resolved.

Food and Drink

You may be asked to limit food intake before the examination. Follow your physician's instructions carefully. If you have kidney disease, do not restrict fluid intake, as adequate hydration is crucial for protecting kidney function during and after contrast administration. In fact, adequate pre- and post-procedural hydration is one of the most important measures to reduce the risk of contrast-induced kidney injury.

How Does Optiray Interact with Other Drugs?

Quick Answer: Optiray can interact with several medications, most notably metformin (requires discontinuation), interleukin-2, vasoconstrictors, general anesthetics, and diuretics. Always inform your healthcare provider about all medications you are currently taking.

Drug interactions with iodinated contrast media can have serious consequences. It is essential that your physician and radiologist are aware of all medications you are taking, have recently taken, or may take. The following interactions are clinically significant:

Metformin – Critical Interaction

The interaction between Optiray and metformin deserves special attention. Metformin is the most commonly prescribed oral medication for type 2 diabetes. Iodinated contrast media can temporarily impair kidney function, and if the kidneys cannot adequately clear metformin from the body, the drug can accumulate to dangerous levels and cause lactic acidosis – a rare but potentially fatal condition. For this reason, metformin must be stopped before the contrast procedure and not restarted until at least 48 hours afterward, and only once kidney function tests confirm that renal function has returned to baseline levels.

Other Interactions

Patients taking beta-blockers may have an attenuated response to epinephrine (adrenaline) if it is needed to treat an anaphylactic reaction to contrast media. Radiologists should be aware of beta-blocker use and may need to use glucagon as an alternative in such emergencies. Additionally, patients on nephrotoxic drugs such as aminoglycosides, NSAIDs, or cisplatin may be at higher risk of contrast-induced kidney injury, and extra precautions regarding hydration and monitoring are warranted.

What Is the Correct Dosage of Optiray?

Quick Answer: Optiray is always administered by a qualified physician or radiologist who determines the appropriate dose based on the specific examination, patient's body weight, age, and overall health. The lowest dose that produces adequate diagnostic images is always used.

Unlike most medications that patients self-administer, Optiray is given exclusively by trained healthcare professionals in controlled clinical settings. Patients do not need to manage their own dosing. The contrast agent is warmed to body temperature (approximately 37°C) before injection to improve patient comfort and optimize the flow characteristics of the solution.

Adults

Children

Optiray 300 is approved for angiography and urography in pediatric patients. Dosing in children is weight-based and determined by the radiologist according to the child's body weight, age, and the specific examination. Lower volumes are used compared to adults, and particular care is taken to minimize radiation exposure and contrast dose in accordance with pediatric imaging guidelines.

For pediatric patients under 3 years of age, including neonates whose mothers received iodinated contrast during pregnancy, thyroid hormone monitoring (TSH and T4) is recommended at 7–10 days and 1 month after administration, due to the potential impact of the iodine load on the immature thyroid gland.

Elderly Patients

Elderly patients may be at increased risk of adverse reactions, particularly contrast-induced kidney injury, due to age-related decline in renal function. Careful assessment of kidney function before the procedure, adequate hydration, and use of the lowest effective dose are especially important in this population. Post-procedural monitoring of kidney function is recommended.

Overdose

What Are the Side Effects of Optiray?

Quick Answer: Like all medicines, Optiray can cause side effects, although not everyone experiences them. Most side effects are mild and transient. The most common effect is a warm sensation during injection. Serious allergic reactions are rare but can be life-threatening.

Side effects associated with Optiray are generally not dose-dependent. In the majority of cases, they are mild to moderate in severity and resolve spontaneously within a short time. However, in very rare instances, serious or life-threatening reactions can occur. Healthcare facilities administering contrast media must always have emergency resuscitation equipment and trained personnel available.

Encephalopathy – Important Safety Information

During or shortly after the radiographic examination, you may experience a transient brain disorder called contrast-induced encephalopathy. This is a rare but recognized complication of iodinated contrast administration. Symptoms may include confusion, hallucinations, visual disturbances (including temporary blindness), seizures, loss of coordination, weakness on one side of the body, speech difficulties, and altered consciousness. If you notice any of these symptoms, inform your healthcare team immediately. This condition is usually self-limiting and resolves within hours to days, but requires prompt medical evaluation to rule out other causes.

How Should Optiray Be Stored?

Quick Answer: Optiray should be stored below 30°C, protected from light and X-ray exposure, in its original carton. It can be kept in a contrast media warmer at 37°C for up to one month. Do not use if discolored or containing particles.

Proper storage of Optiray is essential to maintain its quality and safety. The following storage guidelines apply:

• Temperature: Store at or below 30°C (86°F). Do not freeze. Optiray 300 may be stored for up to one month at 37°C (98.6°F) in a contrast media warmer with circulating air, which is common practice in radiology departments for patient comfort.
• Light protection: Keep the vial or syringe in its original outer carton to protect from light exposure, which can degrade the product over time.
• X-ray protection: Protect from X-ray exposure during storage, as radiation can affect the chemical stability of the contrast agent.
• Visual inspection: Before use, the solution should be visually inspected. Do not use Optiray if the solution appears discolored (it should be clear and colorless to slightly yellow) or if it contains visible particles.
• Expiry date: Do not use after the expiration date printed on the label. The expiration date refers to the last day of the stated month.
• Keep out of reach of children: Although Optiray is only administered in clinical settings, any remaining product should be stored safely out of children's reach.

Optiray is available in colorless glass vials with bromobutyl rubber closures and aluminum caps in sizes of 10, 20, 50, 75, 100, and 150 mL. It is also available in prefilled handheld syringes (30 mL, 50 mL) and power injector syringes (50, 75, 100, 125 mL) made of polypropylene. Any unused product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste.

What Does Optiray Contain?

Quick Answer: Each milliliter of Optiray 300 contains 636 mg of ioversol (equivalent to 300 mg of organically bound iodine) as the active ingredient. Excipients include calcium disodium edetate, tromethamine, tromethamine hydrochloride, and water for injections.

Active Ingredient

The active substance in Optiray is ioversol, a non-ionic, monomeric iodinated contrast agent. Ioversol has three iodine atoms per molecule, which provide the X-ray attenuating properties essential for diagnostic imaging. In Optiray 300, each milliliter contains 636 mg of ioversol, delivering 300 mg of organically bound iodine per milliliter. The iodine is covalently bound to the organic molecule, making it more stable and less likely to cause adverse reactions compared to free iodine.

Excipients

The solution is formulated to have a physiologically compatible osmolality and viscosity, which contributes to better tolerability compared to high-osmolar contrast agents. The pH is adjusted to between 6.0 and 7.4, close to physiological blood pH, further reducing the risk of adverse effects at the injection site and systemically.